Predictors of response to pharmacotherapy in social anxiety disorder: An analysis of 3 placebo-controlled paroxetine trials

Simple item page
dc.contributor.authorStein D.J.
dc.contributor.authorStein M.B.
dc.contributor.authorPitts C.D.
dc.contributor.authorKumar R.
dc.contributor.authorHunter B.
dc.date.accessioned2011-05-15T16:01:57Z
dc.date.available2011-05-15T16:01:57Z
dc.date.issued2002
dc.description.abstractBackground: There is increasing evidence that patients with social anxiety disorder (social phobia) respond to treatment with selective serotonin reuptake inhibitors (SSRIs). Response rates to SSRIs in social anxiety disorder have ranged from at least 50% in controlled trials to up to 80% in open trials. To date, however, there has been little information available about predictors of response to treatment in this disorder. Method: Data from 3 placebo-controlled multicenter trials of paroxetine in DSM-IV social anxiety disorder (N = 829) were analyzed using logistic regression to determine predictors of response. Demographic (age, sex), physiologic (baseline heart rate, baseline mean arterial pressure), clinical (baseline social anxiety symptom severity, baseline disability, duration of illness), and trial variables (paroxetine dose, treatment duration) were included. Results: Only duration of treatment was a statistically significant predictor of treatment response. Further analysis demonstrated that, in paroxetine-treated patients in particular, many nonresponders at week 8 (46/166; 27.7%) were responders at week 12. Conclusion: These data demonstrate that paroxetine is a reasonable choice of treatment in a broad spectrum of patients with social anxiety disorder. An optimal trial of medication should continue beyond 8 weeks.
dc.description.versionArticle
dc.identifier.citationJournal of Clinical Psychiatry
dc.identifier.citation63
dc.identifier.citation2
dc.identifier.issn1606689
dc.identifier.urihttp://hdl.handle.net/10019.1/12233
dc.subjectcitalopram
dc.subjectclonazepam
dc.subjectfluoxetine
dc.subjectfluvoxamine maleate
dc.subjectparoxetine
dc.subjectphenelzine
dc.subjectplacebo
dc.subjectsertraline
dc.subjecttranylcypromine
dc.subjectage
dc.subjectarticle
dc.subjectclinical trial
dc.subjectcontrolled clinical trial
dc.subjectcontrolled study
dc.subjectdisability
dc.subjectdisease duration
dc.subjectdrug efficacy
dc.subjectdrug withdrawal
dc.subjectfemale
dc.subjectheart rate
dc.subjecthuman
dc.subjectlogistic regression analysis
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmean arterial pressure
dc.subjectmulticenter study
dc.subjectprediction
dc.subjectpriority journal
dc.subjectpsychopharmacotherapy
dc.subjectrandomized controlled trial
dc.subjectsex difference
dc.subjectsocial phobia
dc.subjectsymptom
dc.subjectDrug Administration Schedule
dc.subjectFemale
dc.subjectHumans
dc.subjectLogistic Models
dc.subjectMale
dc.subjectParoxetine
dc.subjectPhobic Disorders
dc.subjectProbability
dc.subjectSerotonin Uptake Inhibitors
dc.subjectTime Factors
dc.subjectTreatment Outcome
dc.titlePredictors of response to pharmacotherapy in social anxiety disorder: An analysis of 3 placebo-controlled paroxetine trials
dc.typeArticle
Files
Collections
Stellenbosch University - Scopus Publications